Skip to main content

Neurodegenerative Diseases

2
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Alector
AlectorCA - South SF
1 program
1
LatozinemabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06111014Terminated17Est. Jan 2026
Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
1 program
1
ONO-2808Phase 11 trial
Active Trials
NCT04578028Completed94Est. Oct 2021
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
PC4L solutionsN/A1 trial
Active Trials
NCT05538455Completed558Est. Apr 2023
Parexel
ParexelMA - Boston
1 program
ONO-2808PHASE_1
SciNeuro Pharmaceuticals
SciNeuro PharmaceuticalsChina - Shanghai
1 program
SNP318PHASE_11 trial
Active Trials
NCT05792163Completed76Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlectorLatozinemab
SciNeuro PharmaceuticalsSNP318
Ono PharmaceuticalONO-2808
Integrated BiosciencesPC4L solutions

Clinical Trials (4)

Total enrollment: 745 patients across 4 trials

NCT06111014AlectorLatozinemab

Continuation Study for Latozinemab

Start: Dec 2023Est. completion: Jan 202617 patients
Phase 3Terminated
NCT05792163SciNeuro PharmaceuticalsSNP318

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Start: Mar 2023Est. completion: Nov 202376 patients
Phase 1Completed
NCT04578028Ono PharmaceuticalONO-2808

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

Start: Aug 2020Est. completion: Oct 202194 patients
Phase 1Completed
NCT05538455Integrated BiosciencesPC4L solutions

Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases

Start: Sep 2022Est. completion: Apr 2023558 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.